Open AccessTHE USE OF TOFACITINIB FOR TREATMENT PATIENTS WITH PSORIASIS IN CONDITIONS OF THE DERMATOLOGICAL HOSPITAL
Author(s) -
Э. В. Натарова,
Натарова Элла Валерьевна,
Н. С. Руднева,
Руднева Н. С,
M. S Kuklina,
Куклина М. С,
Ya. Yu. Chumakova,
Чумакова Я. Ю
Publication year - 2017
Publication title -
rossijskij žurnal kožnyh i veneričeskih boleznej
Language(s) - English
Resource type - Journals
eISSN - 2412-9097
pISSN - 1560-9588
DOI - 10.18821/1560-9588-2017-20-4-220-226
Subject(s) - tofacitinib , medicine , psoriasis , observational study , psoriatic arthritis , janus kinase , dermatology , dosing , janus kinase inhibitor , plaque psoriasis , pharmacology , rheumatoid arthritis , cytokine
A growing understanding of the cellular and molecular mechanisms of inflammation in psoriasis and psoriatic arthritis opens the way to the treatment these diseases with the help of new small molecules, associated with the blockade of intracellular signal transduction. Jaqinus®/Xeljanz® (tofacitinib, “Pfizer”) is the first oral inhibitor of Janus kinases for the treatment of chronic moderately severe and severe plaque psoriasiswhich was approved for usage in Russia. The authors also present own local data regarding usage of tofacitinib 10 and 20 mg/day by short course for the treatment group of 13 patients with severe forms of plaque psoriasis in a progressing stage with resistance to prior systemic conventional therapy who were treated at the TDVCD. The efficacy of therapeutic strategies with the use of tofacitinib for patients of the dermatological hospital with the aim of improving and stabilizing of acute process is shown. Further prospective and observational studies to refine the dosing and safety profile of this group of drugs are needed.